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Twentyninc chronic schizophrenics maintained on trifluperazinc treatment were included in the trial 
trifluperazinc was discontinued till relapse oeeurcd. Standard injectable trifluperazinc was reinstituted for 10 
days. This was replaced by weekly dose of 20-40 mg penfluridol orally for a period of d months. Assessment was 
done monthly and side effects were monitored. At the end of h months. 2M patients not only maintained but im-
proved in the psychiatric status. The trial has confirmed that penfluridol is a safe and effective drug which would 
be suitable for maintenance therapy in schizophrenic patients. 
Introduction 
Since the introduction of Chlor-
promazine by Delay and Deniker in early 
fifties the search for effective 
chemotherapeutic agents has not satisfied 
the satiety of scientists in the field. During 
this brief history more than hundred 
neuroleptics have been clinically investi-
gated and approximately one quarter of 
these have been widely employed in clini-
cal practice. 
In long term management of schizop-
hrenic patients studies indicate that stop-
ping maintenance medication brings on a 
relapse. In two large controlled studies of 
released psychiatric patients 45-58% were 
rehospitalised within 2 years (Drieman PM 
et al 1979; Langsley et al 1971). Hogarty 
and Goldberg (1973) reported from a large 
controlled aftercare study that significant 
inverse relationship existed between 
maintenance chemotherapy and rate of re-
lapse in the community. 
Long term drug taking has inherent 
problems of non-compliance. The schizop-
hrenic process also interferes with proper 
intake of medication. Injectable depot pre-
parations have been used, but have the 
disadvantage of provoking severe ex-
trapyramidal reactions. Oral antipsycho-
tics with a long duration of action have 
been possible alternative in the long search 
for an effective maintenance chemothera-
peutic agent. Recent development of the 
diphenylbutyl piperidine series of drugs is 
a significant step in this direction. 
Penfluridol is a long acting orally ef-
fective Diphenylbutylpiperidine in the 
class of pimozide and fluspirilene. 
Penfluridol has a biological half life of 130 
hrs. and peak concentrations occur within 
8 hrs. of injection (Askel Jorgenses 1983). 
Thus penfluridol remains biologically ac-
tive for between one and two weeks fol-
lowing a single oral dose (A.V.P. Mac-
kay 1982) and is the longest acting 
(Lapierre 1978). Penfluridol blocks cent-
ral catecholamine receptors; especially 
dopamine receptors and thus makes it 
a right candidate as an antipsychotic 
drug. 
Recent clinical studies in some centres 
in Europe and North America have shown 
that oral administration of penfluridol can 
provide a relatively safe and adequate con-
trol of schizophrenic patients with a dura-
tion of action of one week (Gallant et al 
1974; Van Paraag et al 1971). 
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The present study was designed to set 
the hypothesis that 
a) Penfluridol administered orally once a 
week in an effective agent in the mainte-
nance therapy of schizophrenic patients 
and 
b) To compare its efficacy with that of 
Trifluoperazine. 
Material and Methods 
Twentynine patients who fulfilled the 
DSM III criteria for schizophrenia; (18 
males and 11 females) ranging in age from 
19 to 52 years were included in the 6 
months trial. All the patients prior to their 
being admitted to the trial were under 
maintenance therapy with Trif-
luoperazine. At the beginning of the trial 
the patients were physically examined, 
routine blood investigations and Liver 
Function Tests were done. The design of 
the study was unique in that there was dis-
continuation of classical neuroleptic 
maintenance treatment till relapse oc-
cured. (Earlier studies switched to 
penfluridol abruptly after discontinuation 
of the classical neuroleptic therapy). Pa-
tients failing to relapse within four weeks 
were withdrawn from the study. The stan-
dard neuroleptic therapy was re-instituted 
with trifluoperazine 4 mg daily given deep 
I.M. for a period of 10 days. Parenteral 
trifluoperazine was used in order to bypass 
the enterohepatic circulation and thus im-
prove the bio-availability of the drug. Trif-
luoperazine was replaced by weekly dose 
of 20-40 mg of penfluridol administered or-
ally. The patients were assessed monthly 
on 36 items questionaire for a period of 6 
months in relation to his/her pre-trial state 
and grouped under the following categories-
marked improvement; maintained; deterio-
ration. The factor composition of 
penfluridol protocol (from ECDEU assess-
ment manual 1976) is given below: 
Factor Composition 
Anxiety depression 
BPRS items 1,2,5,9. our items 
6.7,8,15. 
Anergia 
BPRS items 3,13,16,18 our items 
2,3,16,29. 
Thought disturbance 
BPRS items 4,8,12,1,5 our items 
9,10,11,12. 
Activation 
BPRS items 6,7,17 our items 3,5. 
Hostile suspiciousness 
BPRS items 6.7,17 our items 1,13,14. 
Others: 17,25 Hamilton Scale 
18,22,23,24 Wing's scale 
19,21 Venables 
26 Sleep 
27-31 Side effects 
32-36 Extrapyramidal syndrome 
37 Side effects. 
The analysis of individual patients 
mental status was subjected to statistical 
analysis based on a comparison by paired 
V test at the end of 6 months. 
Results 
Twelve patients showed marked and 
rapid improvement 16 had maintained 
their pretrial mental state i.e. they did not 
show any deterioration but were in a con-
trolled state as they were under former 
neuroleptic treatment. Out of 29 patients 
only a single patient showed some signs of 
deterioration. Of the 16 patients who 
showed maintenance state - 12 had dura-
tion of illness over 12 years. 
On individual items it was noticed that 
there was a significant improvement in the 
reduction of somatic concern (P<0.05) 
and guilt feeling (P<0.()5). Though it did 
not show much improvement on depres-
sive mood (PX1.05) and anxiety (P>0.()5). S.D. SHARMA  407 
Anergia - there was marked improve-
ment in the breaking of emotional barrier 
and in the facilitation of communication 
with the patient (P<0.()1). However, it did 
not make any difference in reducing dis-
orientation in those patients when present 
(P>().05). 
Thought disturbance-there was an 
amelioration of abnormal thought process 
(P<0.()5) and thought content (P<().()5) 
but the perceptual disturbances like hal-
lucinations did not show any change 
(P>0.05). 
Hostility and suspiciousness-There 
was an overall improvement in all the areas 
of suspiciousness; animosity and delusions 
(P«).01). 
In addition, there was improvement 
in work capacity by reduction in social 
withdrawl and enhancement of positive at-
titude to work. 
Side Effects 
Side effects such as restlessness (6) 
moderate sedation (3), tremors (8), 
oculogyric crises (4), rigidity (1). and 
heavy sedation (1) were seen but they were 
less in comparison with previous therapy. 
Discussion 
The above results demostrate the 
superior effect of penfluridol over trif-
luoperazine. The global assessment 
showed that penfluridol was not only able 
to maintain but also improve the psychiat-
ric status of 28 patients over a period of 6 
months. However, it is difficult to state at 
this stage about its superiority over other 
neuroleptics. But with the contemporary 
trend towards outpatient care of schizop-
hrenic patients the use of drugs like 
penfluridol may bring better reward by 
maintaining chronic schizophrenics in re-
mission. 
Otta, Kurland and Slotnick (1974) in a 
study evaluating the safety of penfluridol -
also reportd a reasonably good level of 
therapeutic response to penfluridol. They 
found that 3 out of 4 items of the BPRS 
showed significant difference in favour of 
penfluridol on the items of excitation, 
thinking disorganisation and anergia. 5 of 
6 factors in NOSIE as well as total score 
showed significant improvement in 
penfluridol provide safe and adequate con-
trol of chronic schizophrenics and displays 
efficacy similar to other antipsychotics. 
BaroF Brugmans et al (1970) also 
found penfluridol safe and effective in 
psychiatric symptomatology. They used a 
dose range beginning from 5-10 mg upto a 
maximum of 160-200 mg and found that 
clinically significant effects on vital signs or 
different laboratory tests. Adverse reac-
tions were no more frequent than among 
controlled patients receiving commonly 
used neuroleptic medication. EPSoccured 
at more than 10 mg doses; and sedation 
was virtually absent. Psychiatric tests 
(CCI. NOSIE & BPRS) showed the drug 
as effective as conventional pheno-
thiazines used in their groups. 
One Indian study by Chan-
nabas; wanna and Albert Michael (1987) 
has also found that Penfluridol as once 
weekly oral dose provides adequate and 
safe control of schizophrenia. 
As reported by Tanghc and Ver-
eechen (1972) in our study also the side ef-
fects were mild in nature and could be eas-
ily controlled. 
In conclusion penfluridol appears to 
be effective and safe drug and may prove 
useful as a maintenance medication. 
Penfluridol provides an additional choice 
in the therapeutic armamentarium of 
neuroleptics. 40S PENUFLURIDOL IN THE TREATMENT OE SCHIZOPHRENICS 
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